Product logins

Find logins to all Clarivate products below.


How we identified
the drugs

We combine extensive data sets and expertise to identify potential blockbuster drugs, landscape-shaping treatments and therapeutic game-changers.

Drugs to Watch from Clarivate showcases drugs recently launched and drugs likely to enter the market or meet a consequential milestone this year that are forecast to become blockbusters within five years and/or to transform treatment paradigms (blockbuster being defined by the common $1bn annual sales milestone).

Over 160 of our analysts manually evaluate each drug in its individual context, based on factors such as expected approval or launch dates, competitive landscape, regulatory status, trial results, market dynamics and other factors. They also include novel drugs that, although likely to fall short of blockbuster status, are poised to be therapeutic game-changers.

Our emerging drug selection criteria

In short, candidate drugs included those:

  • In phase 2 or 3 trials, at pre- or registration stage or already launched in 2025.
  • Launched for a new indication that could be impactful on the industry.
  • With total forecast sales of ≥$1bn in 2031 and/or that could significantly transform treatment paradigms.

Our data sources

Our analysts use proprietary Clarivate technologies, tools and techniques to produce the annual Drugs to Watch report.

Cortellis Competitive Intelligence

Make critical portfolio decisions backed by comprehensive pipeline and pharma competitive intelligence

Epidemiology Intelligence
Size your market accurately and understand patient populations with comprehensive epidemiology data
BioWorld

Actionable intelligence on the most innovative therapeutics and medical technologies in development

Cortellis Regulatory Intelligence
Confidently navigate the global regulatory landscape and maintain compliance, now enhanced by AI-powered capabilities through the Regulatory Assistant
Cortellis Clinical Trials Intelligence
Gain insights into clinical trial progression, competitor strategies and protocol design optimization to position your clinical trials for success from day one
DRG Fusion
DRG Fusion is the most configurable, intelligent, and workflow-native analytics platform for commercial life sciences. Powered by uniquely connected real-world data and an AI-driven experience, Fusion empowers you to analyze any disease, from any angle, and solve your most critical commercial challenges.
China In-Depth
Optimize your long-term disease strategy and validate your forecasts with comprehensive Mainland China market intelligence and takeaways
Disease Landscape and Forecast Insights

Optimize your long-term disease strategy and validate your forecasts with comprehensive market intelligence and takeaways.

Clarivate contributors